Robotassisterad minimalinvasiv kirurgi för hjärnstamsblödning (RAINBOW-BSH)
Forskning om minimalt invasiva kirurgiska strategier för hjärnstamsblödning med hjälp av robotik
The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are:
- Establish a multi-center clinical database for brainstem hemorrhage.
- Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits.
- Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning.
Participants in the experimental group will:
- Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture
- Receive conservative non-surgical treatment.
If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Yanbing Yu, M.D.
- Telefonnummer: +86-13901114963
- E-post: yuyanbing123@126.com
Studera Kontakt Backup
- Namn: Yulian Zhang, M.D.
- Telefonnummer: +86-13051581507
- E-post: 398824625@qq.com
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100029
- Rekrytering
- China-Japan Friendship Hospital
-
Kontakt:
- Yulian Zhang, M.D.
- Telefonnummer: +86-13051581507
- E-post: 398824625@qq.com
-
Kontakt:
- Yanbing Yu, M.D.
- Telefonnummer: 13901114963
- E-post: yuyanbing123@126.com
-
Underutredare:
- Xu Yang, M.D.
-
Beijing, Beijing Municipality, Kina, 100049
- Rekrytering
- Aerospace Center Hospital
-
Kontakt:
- Feng Yin, M.D.
- Telefonnummer: +86-13381207600
- E-post: yinf897@163.com
-
Kontakt:
- Hui Chen, M.D.
- Telefonnummer: +86-13810520648
- E-post: 16564583@qq.com
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530021
- Rekrytering
- The First Affiliated Hospital of Guangxi Medical University
-
Kontakt:
- DAQIN FENG
- Telefonnummer: +8619914884494
- E-post: 13807713918@163.com
-
-
Hebei
-
Shijiazhuang, Hebei, Kina, 100190
- Rekrytering
- Hebei Provincial People's Hospital
-
Kontakt:
- Tao Qian, M.D.
- Telefonnummer: +86-15931423666
- E-post: qt1966a@163.com
-
Kontakt:
- Yang Li, M.D.
- Telefonnummer: +86-18632109423
- E-post: 772355464@qq.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekrytering
- Nanjing Drum Tower Hospital
-
Kontakt:
- CHUNHUA HANG
- Telefonnummer: +8613813379309
- E-post: hang1965@nju.edu.cn
-
Nantong, Jiangsu, Kina, 226001
- Rekrytering
- Affiliated Hospital of Nantong University
-
Kontakt:
- JIANHONG SHEN
- Telefonnummer: +8613506287516
- E-post: tysjh@163.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Rekrytering
- The Second Affiliated Hospital of Nanchang University
-
Kontakt:
- HUA GUO
- Telefonnummer: +8613697081718
- E-post: ndefy02014@ncu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Rekrytering
- Huashan Hospital Fudan University
-
Kontakt:
- JIN HU
- Telefonnummer: +8618930174565
- E-post: hujin@fudan.edu.cn
-
Shanghai, Shanghai Municipality, Kina, 201199
- Rekrytering
- Shanghai Minhang District Central Hospital
-
Kontakt:
- FULIN XU
- Telefonnummer: +8618121270156
- E-post: 18918169183@163.com
-
Shanghai, Shanghai Municipality, Kina, 200120
- Rekrytering
- Shanghai East Hospital, Tongji University
-
Kontakt:
- CHUNLONG ZHONG
- Telefonnummer: +8613917920669
- E-post: drchunlongzhong@tongji.edu.cn
-
Shanghai, Shanghai Municipality, Kina, 201508
- Rekrytering
- Jinshan Hospital, Fudan University
-
Kontakt:
- ERSONG WANG
- Telefonnummer: wersong@aliyun +8618930815670
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300350
- Rekrytering
- Tianjin Huanhu Hospital
-
Kontakt:
- JIE ZUO
- Telefonnummer: +8618920195507
- E-post: luckywhg@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310009
- Rekrytering
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Kontakt:
- Gao Chen
- Telefonnummer: +8613738194475
- E-post: d-chengao@zju.edu.cn
-
Jinhua, Zhejiang, Kina, 321000
- Rekrytering
- Jinhua Municipal Central Hospital / Jinhua Hospital Affiliated to Zhejiang University School of Medicine
-
Kontakt:
- MINFENG TONG
- Telefonnummer: +8613646694178
- E-post: Tmfhyj@sina.com
-
Wenzhou, Zhejiang, Kina, 325000
- Rekrytering
- The First Affiliated Hospital of Wenzhou Medical University
-
Kontakt:
- QUN LI
- Telefonnummer: +8615858002900
- E-post: garylina@126.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Participants must meet all of the following inclusion criteria:
- Age ≥18 years at randomization；
- Diagnosed with brainstem hemorrhage via imaging (CT, CTA, etc.)；
- Hematoma volume ≥3 mL；
- Glasgow Coma Scale (GCS) score of 3-12；
- Available for surgery within 48 hours after onset；
- Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage；
- Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements.
Patients will be excluded if they meet any of the following criteria:
- Hematoma involving other regions such as the supratentorial compartment, basal ganglia, thalamus, midbrain, or ventricles.
- Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage；
- Any irreversible coagulation disorder or known coagulopathy; platelet count <100,000/µL; INR >1.4; or use of anticoagulant medication within 7 days before the current hemorrhage；
- Current or probable pregnancy；
- Patients with concurrent severe illness likely to influence outcome assessment；
- Difficulty in follow-up or poor compliance due to any cause.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Robot-assisted minimally invasive puncture and aspiration surgery
The intervention group will receive robot-assisted stereotactic puncture for brainstem hemorrhage |
Positioning and surgical operation will be performed according to the robot navigation system protocols. Preoperative imaging data will be used for precise surgical planning, including the construction of a three-dimensional (3D) preoperative visualization model. The 3D reconstruction and CT data will be imported into the AI robot-assisted stereotactic system, which, after mapping to the patient's skull, automatically designs the surgical target, calculates coordinate values, plans the puncture trajectory, and determines the cranial entry point. Different surgical approaches will be selected based on the location and shape of the hematoma, and individualized parameters, including puncture direction and trajectory length, will be generated for each patient. During the procedure, the robot will assist with stereotactic puncture, while the patient's heart rate and blood pressure are closely monitored.
Andra namn:
According to the "Chinese Neurosurgical Expert Consensus on the Diagnosis and Treatment of Primary Brainstem Hemorrhage", conventional medical treatment includes oxygen therapy, specialized nursing care, blood pressure control (maintaining BP at ≤140/90 mmHg), sedation, intracranial pressure reduction, arousal promotion, gastric protection, maintenance of internal homeostasis, infection prevention, neuro-nutrition, brain function support, nutritional support, and overall systemic management; For comatose patients, ensure a patent airway, provide nebulization and sputum clearance, prevent respiratory depression, and improve respiratory function. Closely monitor the patient's condition and provide active symptomatic treatment as needed. Regular cranial CT scans are performed to evaluate intracranial status, and in cases of ventricular hemorrhage or obstructive hydrocephalus, lateral ventricular puncture and drainage may be performed.
Andra namn:
|
|
Aktiv komparator: Standard medical management
The control group will undergo conventional medical conservative management. |
According to the "Chinese Neurosurgical Expert Consensus on the Diagnosis and Treatment of Primary Brainstem Hemorrhage", conventional medical treatment includes oxygen therapy, specialized nursing care, blood pressure control (maintaining BP at ≤140/90 mmHg), sedation, intracranial pressure reduction, arousal promotion, gastric protection, maintenance of internal homeostasis, infection prevention, neuro-nutrition, brain function support, nutritional support, and overall systemic management; For comatose patients, ensure a patent airway, provide nebulization and sputum clearance, prevent respiratory depression, and improve respiratory function. Closely monitor the patient's condition and provide active symptomatic treatment as needed. Regular cranial CT scans are performed to evaluate intracranial status, and in cases of ventricular hemorrhage or obstructive hydrocephalus, lateral ventricular puncture and drainage may be performed.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Survival rate
Tidsram: 60 days
|
60 days survival rate after follow-up |
60 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Ordinal shift in mRS scores at 60 days and 6 months
Tidsram: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Favorable functional outcome at 60 days and 6 months (mRS 0-1)
Tidsram: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Functional independence at 60 days and 6 months (mRS 0-2)
Tidsram: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Health-related quality of life (HRQoL) at 60 days and 6 months, assessed by the EQ-5D-5L questionnaire
Tidsram: 60 days and 6 months
|
Health-related quality of life (HRQoL) at 60 days and 6 months, assessed by the EQ-5D-5L questionnaire |
60 days and 6 months
|
|
Utility-weighted mRS at 60 days and 6 months
Tidsram: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Cognitive function at 60 days and 6 months
Tidsram: 60 days and 6 months
|
Cognitive function at 60 days and 6 months |
60 days and 6 months
|
|
Total length of hospital stay
Tidsram: 60 days
|
Total length of hospital stay |
60 days
|
|
Costs during hospitalization
Tidsram: 60 days
|
Costs during hospitalization |
60 days
|
|
ICU length of stay
Tidsram: 60 days
|
ICU length of stay |
60 days
|
|
Brainstem hematoma clearance rate on postoperative days 1, 3, and 7
Tidsram: 1, 3, and 7 days
|
The change in hematoma volume compared to the preoperative CT scan was assessed 1, 3, and 7 days postoperatively. |
1, 3, and 7 days
|
|
Incidence of related complications within 14 days, including pneumonia, aphasia, seizures, and lower-extremity deep vein thrombosis
Tidsram: 14 days
|
Incidence of related complications within 14 days, including pneumonia, aphasia, seizures, and lower-extremity deep vein thrombosis |
14 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Yanbing Yu, M.D., China-Japan Friendship Hospital
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 01084205031
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The study has not yet begun; we will decide once recruitment starts.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .